ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Updates

Clear All

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on GSK various products

GSK has informed us that due to a machinery defect with the printing line, a small number of packs may not have the batch number and expiry date printed on the outer cartons. The correct information is printed on the blister pack and there is no concern with the product quality.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
2881316BEECHAMS AIO TABLETSGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
2847317PIRITEZE ALLERGY ONE-A-DAY TABGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
4093456PIRITEZE ALLERGY TABLETSGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
4093449PIRITEZE TABLET ALLERGY 30SGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
2132074PIRITON ALLERGY TABLETSGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
3339199PIRITON ALLERGY TABLETSGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
0076083DAY NURSE CAPGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE
0092767NIGHT NURSE CAPSGLAXO SMITH KLINEPLEASE REFER TO MHRA WEBSITE

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert

For more information or medical information queries, please contact GSK Customer Relations at 0800783 8881 or email customer.relations@gsk.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This is a caution in use only we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Levofloxacin 500mg Tablets

TEVA UK Limited has informed us that the Product Code/GTIN (PC) number found on the above batches is incorrect. The GTIN number that should have been allocated for this batch of tablets is 05017007064459, however, 05017007064435 was applied in error which scans the batches as Levofloxacin 250mg Tablets. The product packed, the blister primary data, PIL primary data and carton primary data were confirmed as correct for a Levofloxacin 500mg Tablet batch.

 

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
8426322LEVOFLOXACIN TAB 500MGTEVA UK105362
1159250LEVOFLOXACIN TAB 500MGTEVA UK105362
1162205LEVOFLOXACIN TAB 500MGTEVA UK105362
1161645LEVOFLOXACIN TAB 500MGTEVA UK105362

For customer services queries, please contact general.enquiries@tevauk.com or telephone the Freephone number 0800 590 502

For medical enquiries and/or suspected adverse reaction reporting, please contact medinfo@tevauk.com or telephone 020 7540 7117

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert.

This is a caution in use only we are not accepting stock returns

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Paracetamol 250mg/5ml Oral Suspension

Rosemont Pharmaceuticals Ltd has informed us of an error in the barcode and GTIN number of the label on the bottle of the above batches. When scanned, the barcode identifies the bottle as Paracetamol 120ml/5ml Oral Suspension instead of Paracetamol 250mg/5ml Oral Suspension. The dm&d browser website also identifies this GTIN number and barcode incorrectly as Paracetamol 120ml/5ml Oral Suspension.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
7012784PARACETAMOL SUSP 250MG/5MLROSEMONT PHARMAEUTICALS9AL0061
9CL0026
9DL0025
9EL0021
9GL0028
9JL0028
9JL0056
9KL0030
9LL0066
9LL0020
9ML0054

For Customer services queries, please contact Rosemont.customerservices@perrigouk.com or on 0113 244 1999

For medical queries, please contact RosemontPharmacovigilance@perrigouk.com or on 0113 244 1400


For product quality queries, please contact RosemontQAComplaints@perrigouk.com or on 0113 244 1400


Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This is a caution in use only we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Zamadol SR 50 mg prolonged-release hard capsules

Mylan UK Healthcare Ltd has informed us that the GTIN barcode applied on the above batches is incorrect. The GTIN number that should have been allocated for these batches of capsules is 05060035240173, however, 05060035241477 was applied in error which scans the batches as Zamadol Melt Tablet 50mg. All other information on the carton and label, including the EAN barcode is correct for the above batches of Zamadol SR 50 mg prolonged-release hard capsules.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
2427003ZAMADOL SR CAP 50MGMYLAN UK HEALTHCARE8L221D
9B225A

For more information or medical information enquiries please contact Mylan UK Healthcare Ltd. Medical Information Department on +44(0) 1707 853000 or via email on Info.uk@mylan.co.uk
 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

This is a caution in use only we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Esmya Tab 5mg

Gedeon Richter (UK) Ltd is recalling all unexpired stock of the above products from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine. To protect patients while a safety review is conducted, the European Medicines Agency's safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
3707510ESMYA TAB 5MGGEDEON RICHTER LTDALL STOCK

For stock control and/or medical information enquiries please contact Gedeon Richter (UK) Ltd on +44 (0) 1279 406 759
 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Beconase Aqueous Nasal Spray GSK

Update: Returns for credit must be received by Friday 20th March 2020

Glaxo Wellcome UK Ltd T/A GSK has informed us of an issue related to error in the decommissioning of the below batch. Upon decommissioning at the pharmacy and when scanning the serialised 2D code, the status of packs may report as ‘DESTROYED.' Although there is no risk to product quality, any remaining stock should be quarantined and returned.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
383307BECONASE AQ NASAL 50MCGGLAXOSMITHKLINE UK LTDK84X

For stock control enquiries please contact 0800 221441.

For medical information enquiries please contact ukmedinfo@gsk.com , via the Live Chat facility or on 0800 221 441 (option 2).

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Beconase Aqueous Nasal Spray GSK

Update: Returns for credit must be received by Friday 20th March 2020

Glaxo Wellcome UK Ltd T/A GSK has informed us of an issue related to error in the decommissioning of the below batch. Upon decommissioning at the pharmacy and when scanning the serialised 2D code, the status of packs may report as ‘DESTROYED.' Although there is no risk to product quality, any remaining stock should be quarantined and returned.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
383307BECONASE AQ NASAL 50MCGGLAXOSMITHKLINE UK LTDK84X

For stock control enquiries please contact 0800 221441.

For medical information enquiries please contact ukmedinfo@gsk.com , via the Live Chat facility or on 0800 221 441 (option 2).

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Emerade Auto-Injector 150 Bausch & Lomb UK

Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerade 150 microgram auto-injectors (also referred to as pens) from patients due to an error in one component of the auto-injector believed to cause some pens to fail to activate and deliver adrenaline.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
3849221EMERADE 150 AUTO-INJECTORBAUSCH & LOMB UKALL STOCK

For stock enquiries please contact Bausch & Lomb Customer Services, Tel: 020 8781 2991
 

For medical information enquiries please contact the Pharmacovigilance and Medical Information Officer, Tel: 0208 781 5523, Email: Pharmacovigilance.UK@bausch.com

Email: Pharma_CS@bausch.com - please note, only in-date pens that are returned by patients, will be refunded, (i.e. expiry date of March 2020 onwards).

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Tetrabenazine Tab 25mg AOP Orphan Pharmaceuticals AG

AOP Orphan Pharmaceuticals AG is recalling all unexpired stock of the below batch of Tetrabenazine 25 mg tablets (from pharmacies and wholesalers) as a precautionary measure due to out of specification results for the assay, obtained during routine stability testing.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
6838841TETRABENAZINE TAB 25MGAOP Orphan Pharmaceuticals AGT1704UK
3580073TETRABENAZINE TAB 25MGAOP Orphan Pharmaceuticals AGT1704UK

For more information or medical information queries, please contact medinfo@aoporphan.com.

For stock control queries, please contact orderservice@aoporphan.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Alliance Healtchare do not stock this batch therefore we are not accepting stock returns.
 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on Oxylan Prolonged-Release Tablets

G.L Pharma GmbH T/A Healthcare Pharma Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the specified batches is missing important safety relevant text changes.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
6359814OXYCODONE PR TAB 10MGHealthcare Pharma Ltd9F115A
9F116A
6359822OXYCODONE PR TAB 20MGHealthcare Pharma Ltd9J114A
6359830OXYCODONE PR TAB 40MGHealthcare Pharma Ltd9F119A
6359798OXYCODONE PR TAB 80MGHealthcare Pharma Ltd9F120A
8113458OXYCODONE SR TAB 10MGHealthcare Pharma Ltd9F115A
9F116A
8456030OXYCODONE SR TAB 20MGHealthcare Pharma Ltd9J114A
8456014OXYCODONE SR TAB 40MGHealthcare Pharma Ltd9F119A
8455917OXYCODONE SR TAB 80MGHealthcare Pharma Ltd9F120A
3726122OXYCODONE PR TAB 10MGHealthcare Pharma Ltd9F115A
9F116A
3726130OXYCODONE PR TAB 20MGHealthcare Pharma Ltd9J114A
3726148OXYCODONE PR TAB 40MGHealthcare Pharma Ltd9F119A
3726155OXYCODONE PR TAB 80MGHealthcare Pharma Ltd9F120A
1196971OXYCODONE PR TAB 80MG/td>Healthcare Pharma Ltd9F120A

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert.

For more information or medical information queries, please contact: GL Pharma GmbH on +43 3136 82577 or office@gl-pharma.at.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

 

If you have any questions, then please contact your local Service Centre Customer Services team.